Engineering of Crystalline Combination Inhalation Particles of a Long-Acting β2-agonist and a Corticosteroid

被引:0
作者
Chonladda Pitchayajittipong
Jagdeep Shur
Robert Price
机构
[1] University of Bath,Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology
来源
Pharmaceutical Research | 2009年 / 26卷
关键词
combination products; dry powder inhaler; glucocorticosteroid; long-acting β-agonist; SAX;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:2657 / 2666
页数:9
相关论文
共 87 条
  • [1] Barnes PJ(2003)Chronic obstructive pulmonary disease: molecular and cellular mechanisms Eur Respir J 22 672-688
  • [2] Shapiro SD(2008)Immunology of asthma and chronic obstructive pulmonary disease Nat Rev Immunol 8 183-192
  • [3] Pauwels RA(2007)Global alliance against chronic respiratory diseases Allergy 62 216-223
  • [4] Barnes PJ(1994)Added salmeterol Lancet 344 219-224
  • [5] Bousquet J(2001) higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid J Allergy Clinical Immunol 107 783-789
  • [6] Dahk R(2007)Addition of salmeterol to low-dose fluticasone Drugs 67 2383-2406
  • [7] Khalteev N(2005) higher-dose fluticasone: an analysis of asthma exacerbations Curr Allergy Asthma Rep 5 123-129
  • [8] Greening AP(2007)Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease Curr Opin Pulm Med 13 90-97
  • [9] Ind PW(2002)Combination therapy of long-acting beta agonists and inhaled corticosteroids in the management of chronic asthma Eur Respir J 19 182-191
  • [10] Northfield M(2003)Do chronic inhaled steroids alone or in combination with a bronchodilator prolong life in chronic obstructive pulmonary disease patients? J Allergy Clinical Immunol 112 29-36